Navigation Links
BYDUREON (TM) FDA Review Timeline Set with PDUFA Action Date of October 22, 2010
Date:5/6/2010

ee-on) is the proposed brand name for exenatide once weekly. It is an investigational, extended-release medication for type 2 diabetes designed to deliver continuous therapeutic levels of exenatide in a single weekly dose. BYDUREON is a once-weekly formulation of exenatide, the active ingredient in BYETTA, which has been available in the U.S. since June 2005 and is used in approximately 60 countries worldwide to improve glycemic control in adults with type 2 diabetes. BYDUREON and BYETTA belong to the glucagon-like peptide-1 (GLP-1) receptor agonist class of medications.

About Diabetes

Diabetes affects more than 24 million people in the U.S. and an estimated 285 million adults worldwide (i, ii). Approximately 90-95 percent of those affected have type 2 diabetes. Diabetes is the fifth leading cause of death by disease in the U.S. and costs approximately $174 billion per year in direct and indirect medical expenses (iii).

According to the Centers for Disease Control and Prevention's National Health and Nutrition Examination Survey, approximately 60 percent of people with diabetes do not achieve their target blood sugar levels with their current treatment regimen (iv). In addition, 85 percent of type 2 diabetes patients are overweight and 55 percent are considered obese (v). Data indicate that weight loss (even a modest amount) supports patients in their efforts to achieve and sustain glycemic control (vi, vii).

About BYETTA® (exenatide) injection

BYETTA is the first FDA-approved GLP-1 receptor agonist for the treatment of type 2 diabetes. BYETTA exhibits many of the same effects as the human incretin hormone glucagon-like peptide-1 (GLP-1). GLP-1 improves blood sugar after food intake through multiple effects that work in concert o
'/>"/>

SOURCE Amylin Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
2. Thoratec Announces HeartMate II(R) PMA Will be Reviewed by FDA Advisory Panel
3. Amyris Biotechnologies Co-Founder Neil Renninger Named to Technology Reviews Prestigious TR35 List of Top Young Innovators
4. Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiogaphic Data Safety Monitoring Board Review
5. Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiographic Data Safety Monitoring Board Review
6. AEterna Zentaris Announces Outcome of Managements Strategic Review
7. Thomson Scientific Publishes Who Is Making The Biggest Splash? - A Quarterly Review of Scientific Literature on Drugs and Therapies From April - June 2007
8. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
9. Neurobiological Technologies, Inc. (Nasdaq: NTII) Q1/08 Review Issued By Scimitar Equity Research, Inc.
10. BioMS Medicals phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
11. BioMS Medicals pivotal international multiple sclerosis trial receives positive review from Data Safety Monitoring Board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/1/2015)... , April 1, 2015  Spherix Incorporated (Nasdaq: ... to the fostering and monetization of intellectual property, ... privately held full service global investment bank specializing ... an industry note featuring Spherix. The ... a Senior Analyst at Chardan, was published on ...
(Date:4/1/2015)... , April 1, 2015 ... developing novel biological drugs to treat cancer, viral ... announce the appointment of Christina Coughlin ... responsible for providing medical and regulatory leadership to ... Dr. Coughlin has extensive experience in ...
(Date:3/31/2015)... Materials in Society Lecture Series ... 30 2015   Elsevier , a world-leading ... and publishing home of Materials Today , announced that ... Materials in Society  Lecture Series . The ... International Conference on Materials for Advanced Technologies (ICMAT) ...
(Date:3/31/2015)... SALT LAKE CITY , March 31, 2015 /PRNewswire-USNewswire/ ... second milestone with the selection of ten proposals ... The MCRI is the first patient-led, scientifically validated ... patients. Stage 2 of the MCRI ... "After careful review of a large number of ...
Breaking Biology Technology:Chardan Capital Issues Industry Note Covering Spherix 2Chardan Capital Issues Industry Note Covering Spherix 3Immunocore Appoints Dr. Christina Coughlin as Chief Medical Officer 2Immunocore Appoints Dr. Christina Coughlin as Chief Medical Officer 3Immunocore Appoints Dr. Christina Coughlin as Chief Medical Officer 4Elsevier Materials Science Council Introduces the Materials in Society Lecture Series at the International Conference on Materials for Advanced Technologies (ICMAT) 2Elsevier Materials Science Council Introduces the Materials in Society Lecture Series at the International Conference on Materials for Advanced Technologies (ICMAT) 3Myeloma Crowd Research Initiative Selects 10 High-Risk Multiple Myeloma Proposals For Further Review 2
... Ltd.,(SWX: ARPN) today announced that Dr Jurgen Raths will ... Raths commands extensive,knowledge in the commercialisation of drugs for ... built and lead the European,Critical Care sales, medical and ... At the Annual General Meeting of 7 May, ...
... ,Exelixis, Inc. (Nasdaq: EXEL ) announced today that ... Exelixis, will present at the,Morgan Stanley Global Healthcare Unplugged ... 30, 2008. Dr. Scangos will discuss updates to,the company,s ... be webcast and may be accessed in the Event,Calendar ...
... Inc. (Nasdaq: IDIX ) announced today that ... upcoming Morgan Stanley Global,Healthcare Unplugged Conference on Wednesday, ... Ritz Carlton in Key Biscayne, Florida., The ... can be,accessed under "Calendar of Events" in the ...
Cached Biology Technology:Leadership Change to Enable Arpida to Become a Fully Integrated Pharmaceutical Company 2Leadership Change to Enable Arpida to Become a Fully Integrated Pharmaceutical Company 3Leadership Change to Enable Arpida to Become a Fully Integrated Pharmaceutical Company 4
(Date:4/1/2015)... April 1, 2015   Medisafe ™, the leading ... across iOS and Android smartphones ... biofeedback into the platform to allow patients to track ... the first time, patients will be able to visualize ... impacts important biometrics, such as glucose levels and blood ...
(Date:3/24/2015)... , Mar. 24, 2015 Research and Markets ... the "Global Iris Recognition Market 2015-2019" report ... Global Iris Recognition market to grow at a CAGR ... This report covers the present scenario and the growth ... period 2015-2019. To calculate the market size, the report ...
(Date:3/23/2015)... March 23, 2015   HOYOS Labs , a ... today announced that the Company will demonstrate multiple biometrics-based ... and consumers at Connect:ID on March 23 through 25, ... Labs will highlight the IEEE Biometric Open Protocol Standard; ... and enterprise access control system. BOPS was invented by ...
Breaking Biology News(10 mins):Medisafe Announces Launch of Biometric Integration, Enabling Patients to Stay Adherent to Their Meds and See Tangible Health Results 2Global Iris Recognition Market 2015-2019 with 3M Cogent, Bioenable Technologies, Cross Match Technology, Iris ID Systems & Safran Dominating 2HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 2HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 3
... be the impact of the next green revolution on global ... climate change? To what extent can biofuels help make America ... be discussed at the International Annual Meetings of the American ... and Soil Science Society of America (SSSA), Oct. 31-Nov. 3 ...
... NY, October 28, 2010Mary Ann Liebert, Inc. announces the ... area of systems neuroscience, Brain Connectivity . This ... source of cutting-edge basic and clinical neuroscience research aimed ... the brain and how these connections are altered by ...
... by Lupus Research Institute-funded investigator Emily Baechler Gillespie, PhD, at ... clinical laboratory for development and could soon result in a ... to determine when a lupus flare is imminent. ... way to predict when a person with systemic lupus is ...
Cached Biology News:Media alert: Agronomists, crop and soil scientists to convene in Long Beach 2New Brain Connectivity journal captures latest advances in neuroscience research 2New clinical test to predict lupus flares moves closer to the market 2
... (Intein Mediated Purification with an Affinity Chitin-binding ... engineered protein splicing elements (termed inteins) to ... column (1-4) (Figures 1 and 2). This ... systems by its ability to separate a ...
... Analysis Note: The kit contains all ... convenient determination of NADPH-cytochrome c reductase activity ... purified microsomes [endoplastic reticulum (ER)]. It has ... tissues such as liver, kidney, brain, spleen, ...
... provides the reagents to efficiently differentiate ... myotubes. By efficiently promoting myogenic differentiation, ... in studies examining myogenesis, transcription factor ... muscle cell replacement therapy. By providing ...
... CHEMICON's Cell Transformation Detection Assay is an ... is considered the most stringent assay for ... this assay, cells (pre-treated with carcinogens or ... in soft agar medium for 21-28 days. ...
Biology Products: